Related Experiment Video
Updated: Jul 12, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Abstract:
In the LITESPARK-005 and -003 trials, the HIF-2α inhibitor looks effective in advanced clear-cell renal cell carcinoma, both as monotherapy and in combination with VEGFR tyrosine kinase inhibitors. The results favor expanding belzutifan's use beyond von Hippel-Lindau disease-associated cancers, its only current indication.
Insights
Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, shows promise for advanced clear-cell renal cell carcinoma. These findings support its potential use beyond von Hippel-Lindau disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Clear-cell renal cell carcinoma (ccRCC) is an aggressive cancer.
- Current treatments for advanced ccRCC have limitations.
- Belzutifan targets hypoxia-inducible factor-2α (HIF-2α).
Purpose of the Study:
- To evaluate the efficacy of belzutifan in advanced clear-cell renal cell carcinoma.
- To assess belzutifan as monotherapy and in combination with VEGFR tyrosine kinase inhibitors.
Main Methods:
- Analysis of data from the LITESPARK-005 and LITESPARK-003 clinical trials.
- Inclusion of patients with advanced clear-cell renal cell carcinoma.
Main Results:
- Belzutifan demonstrated effectiveness in treating advanced ccRCC.
- Efficacy was observed both as a single agent and in combination therapy.
- The inhibitor showed a favorable safety profile.
Conclusions:
- Belzutifan is a potential new treatment option for advanced ccRCC.
- Results suggest expanding belzutifan's indication beyond von Hippel-Lindau disease-associated cancers.
- Further research is warranted to confirm long-term outcomes.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018